.-The uterine vasculature plays an important role during pregnancy by providing adequate perfusion of the maternal-fetal interface. To this end, substantial remodeling of the uterine vasculature occurs with consequent changes in responsiveness to contractile agents. The purpose of our study was to characterize the vasorelaxant effects of estrogens on vascular smooth muscles of the rat uterine artery during pregnancy and to evaluate the involvement of estrogen receptors (ESR) and nitric oxide synthases (NOS). To do so, we measured NOS expression in the whole uterine and mesenteric circulatory bed by Western blotting. Vasorelaxant effects of 17␤-estradiol (17␤-E 2) were assessed on endothelium-denuded uterine arteries with wire myographs in the absence and presence of pharmacological modulators [nitro-L-arginine methyl ester (L-NAME), ICI-182780, tamoxifen]. All experiments were performed on arteries from nonpregnant (NP) and late pregnant (P) rats. In the uterine vasculature of the latter group, NOS3 (endothelial NOS) expression was increased, while NOS1 (neuronal NOS) was reduced compared with NP rats. Expression of the NOS2 (inducible NOS) isoform was undetectable in the two groups. Both 17␤-E 2 and 17␣-E2 induced uterine artery relaxation, but the latter evoked lower responses. Endotheliumdenuded arteries from NP rats showed larger relaxation with 17␤-E 2 than P rats. This larger relaxation disappeared in the presence of L-NAME. The ESR antagonist ICI-182780 did not affect acute relaxation with 17␤-E 2 and 17␣-E2. Moreover, membrane-nonpermeant 17␤-E2:BSA (estradiol conjugated to bovine serum albumin) did not induce any vasorelaxation. Our results indicate that estrogens exert direct acute vasorelaxant effects in smooth muscles of the rat uterine artery that are mediated by mechanisms independent of ESR activation, but with some stereospecificity. Part of this effect, in NP rats only, is due to nitric oxide produced from muscle NOS1.
estrogens; pregnancy THE UTERINE VASCULATURE plays a pivotal role during pregnancy, being responsible for adequate perfusion of the maternal-fetal interface. To achieve this goal, the substantial remodeling of the uterine vasculature that occurs is characterized in the rat by hypertrophy and hyperplasia of all components of the vessel walls (10) . However, the mechanisms involved are still unclear. Pregnancy-induced remodeling of the uterine vasculature results in several functional alterations, such as increased vascular reactivity to different vasoconstrictors (39) , while reactivity is reduced in systemic arteries (24, 38) .
Pregnancy is also accompanied by major hormonal changes, especially of sex steroids. In women, the plasma concentrations of estradiol (E 2 ) range between 0.1 and 0.4 ng/ml during the normal menstrual cycle (1) . After conception, the E 2 serum level increases progressively until it reaches 6 -30 ng/ml at term (21) . In nonpregnant rats, E 2 ranged from 3 to 19 pg/ml during the estrous cycle, rising to 30 -57 pg/ml on the last (22nd) day of gestation (15, 20) . E 2 has been shown to augment blood flow in the uterine vasculature (22, 32) . Given the high exposure of the utero-placental bed to the direct and massive secretion of estrogens during gestation, these hormones should play a significant role in the uterine arterial circulation during pregnancy. Estrogen may act via two different pathways: genomic and nongenomic (2) . The simplified classical view of the genomic pathway needs estrogen to bind estrogen receptor (ESR1) (formerly ER␣) or ESR2 (formerly ER␤), favoring dimerization. The dimer formed can regulate the transcription of target genes that have estrogen response element sequences in their promoter region. On the other hand, estrogen has been reported to induce some of its effects in a short period of time that could not involve new protein synthesis. These rapid actions of estrogen, referred to as nongenomic actions, could arise from endothelial cell activation or occur directly on vascular smooth muscle (VSM) cells (VSMC). Many studies have disclosed that arterial relaxation mediated by estrogen could result from endothelial cell activation, which releases nitric oxide (NO) (7) and leads to cGMP pathway activation in VSMC that could activate calcium-activated potassium channels (33) . However, this pathway is probably not the main route through which E 2 elicits vasorelaxation, because it has been demonstrated several times that E 2 can relax endotheliumdenuded arteries (9, 18) . With the use of pharmacological levels of E 2 , vascular relaxation in the absence of endothelium was correlated with decreased Ca 2ϩ influx (17, 40) , increased K ϩ efflux (41, 44) , and intracellular cAMP elevation (25) in VSMC. However, it has been discerned in the porcine coronary artery that E 2 relaxation of VSM requires protein kinase G activation by augmenting cAMP and then possibly opening large-conductance Ca 2ϩ -activated K ϩ channels (BK Ca ) (18) . A more recent study suggested that E 2 -induced relaxation involves NO activation of BK Ca in human coronary smooth muscle cells after stimulation of neuronal nitric oxide synthase (nNOS, NOS1) (16) .
In addition, seven-transmembrane G protein-coupled receptor 30 (GPR30) has been reported to trigger rapid cellular signaling when activated by estrogen (14) . Binding to this receptor was found to be highly specific to 17␤-E 2 , with 17␣-E 2 having much less affinity, similar to that of these compounds for ESR (29) . GPR30 has been localized in the cytoplasm (13) and probably in the endoplasmic reticulum (29) , possibly with a small GPR30 pool at the plasma membrane (12) . It has also been shown that GPR30, expressed intracellularly, is capable of initiating cellular signaling, and insufficient GPR30 is expressed on the cell surface to initiate signaling in response to impermeable ligands [E 2 :bovine serum albumin (BSA)] (30) .
NOS are responsible for the production of NO, a volatile gas with well-known vasorelaxant properties on vascular tissues. NOS exist in three isoforms: NOS3 [endothelial NOS (eNOS)], mainly present in the vascular endothelium; NOS1 (nNOS), present in neurons and innervated tissues, such as smooth muscles; and NOS2 [inducible NOS (iNOS)], inducible and expressed ubiquitously. Several studies have reported that NOS3 expression is increased in the uterine vasculature during estrogen treatment, the follicular phase, and pregnancy, suggesting that endothelially generated NO is involved in the vasorelaxant actions of E 2 (23, 27, 28) . However, little is known about changes in NOS2 and NOS1 expression in uterine arteries during pregnancy. NOS1 expression has been shown to be completely abolished in the VSMC of human umbilical cords after preeclamptic pregnancy (36) .
Since increased NOS3 expression in the uterine arterial endothelium during pregnancy is well-documented, what are the direct effects of E 2 on uterine arterial smooth muscle (in the absence of endothelium)? How are these effects modulated during pregnancy in regard to the significant remodeling that occurs in arterial walls during this condition? Our study was designed to characterize the acute effect of estrogens on VSM of uterine arteries, determine how it is affected by pregnancy, and establish whether ESR and NO participate in the acute relaxant action of E 2 . We hypothesized that the acute action of 17␤-E 2 on endothelium-denuded uterine arteries is mediated by a pathway independent from ESR but involving some participation of nonendothelial NOS.
MATERIALS AND METHODS
Animals. Female Sprague-Dawley rats (Charles River Canada, St-Constant, QC, Canada; total of 120) weighing 225-250 g were mated with fertile males. The morning on which spermatozoa were found in vaginal smears was considered day 1 of pregnancy. Virgin rats of the same age (Ϸ14 -15 wk of age) served as controls without consideration of the stage of the estrous cycle. All animals had ad libitum access to food (Teklad global 18% protein rodent diet, Harlan Teklad; Montreal, QC, Canada) and tap water. They were killed by decapitation on day 22 of pregnancy (parturition on day 23). Their uterine horns and small intestine with attached vasculature were removed and placed in cold oxygenated Krebs bicarbonate solution of the following composition (in mmol/l): 118 NaCl, 4.65 KCl, 25 NaHCO3, 2.5 CaCl2, 1.18 MgSO4, 1.18 KH2PO4, and 5.5 dextrose. The uterine vasculature was isolated by blunt dissection of fat and connective tissues. The blood vessels of one uterine horn were detached from the uterus, frozen immediately in liquid nitrogen, and kept at Ϫ80°C until being used for Western blots. The main uterine artery of the other horn was prepared for myotropic activity experiment (see below). The mesenteric vascular bed was prepared in a similar way with blunt dissection of fat and connective tissues, detached from the intestine body, and frozen rapidly in liquid nitrogen. This gave a small vascular tree composed of the superior mesenteric artery down to the fourth branch. All animals were housed under controlled light (6 AM-6 PM) and temperature (21 Ϯ 3°C).
The protocols were approved by the local animal care committee, which is accredited by the Canadian Council on Animal Care.
Western blotting. Frozen tissues were powdered with a mortar and homogenized in Tris buffer (mmol/l: 250 Tris ⅐ HCl, 10 EDTA, 10 EGTA, pH 7.4). For each uterine artery preparation, we pooled the vasculature of two or three animals to obtain enough protein per sample. The homogenate was centrifuged at 3,000 rpm for 10 min. Protein concentration in the supernatant was measured by Bradford assay (Bio-Rad, Mississauga, ON, Canada) (4). Proteins (45 g/well) were separated on sodium dodecyl sulfate-polyacrylamide gels (7.5%) and transferred to nitrocellulose membranes. The membranes were then incubated in blocking solution (Tris-buffered saline-Tween-5% skim dry milk) for 30 min at room temperature. They were then kept overnight at 4°C with primary antibody, washed, and incubated with horseradish peroxidase-conjugated secondary antibody for 30 min at room temperature. Protein loading was estimated on the same gel by cutting the membrane in two and using mouse anti-␤-actin primary antibodies on the lower part. Immunoreactive bands were visualized with the enhanced chemiluminescence (ECL) detection system. The samples were compared by scanning densitometry with Alpha Imager software (Alpha Innotech, San Leandro, CA). The antibodies and optimal dilution were anti-NOS3 mouse IgG1 clone 3 (no. 610297; 1/1,000), anti-NOS2 mouse IgG1 clone 54 (no. 610432; 1/5,000), anti-NOS1 mouse IgG2a clone 16 (no. 610309, BD Biosciences Pharmigen, San Diego, CA; 1/1,000), anti-␤-actin mouse IgG1 clone AC-15 (no. ab6276, Abcam, Cambridge, MA; 1/10,000), and antimouse IgG horseradish peroxidase-linked whole antibody from sheep (no. NA931; 1/2,000) (ECL kit, Amersham Biosciences, Baie d'Urfé, QC, Canada).
Myotropic activity of uterine arteries. The main uterine arteries in the middle portion along the uterine horn were cleaned of fat and connective tissues, and rings (1.5-2.0 mm) were prepared and mounted in wired myographs as described previously (39), with some modifications. For instance, the endothelium was removed by passing Triton X-100 (0.03% vol/vol) in the artery before its mounting on myograph supports similarly to the method of Connor and Feniuk (11). The passive tension applied on the uterine arteries was equivalent to 60 mmHg (L 60), which is the passive circumference that the arterial segment would have had at this transmural pressure.
After the arterial segments were set up in myographs, they were stretched three times to minimize subsequent hysteresis and allowed to equilibrate (10 min) in the absence of passive tension. The segments were stretched in steps of ϳ50 m in diameter until ϳ2-3 mN/mm (1 mN ϭ 102 mg) of wall tension was reached. The vessels were held at each length for 2-3 min, and wall tension was recorded. The data were fitted to the exponential curve y ϭ Ae ␤c to evaluate L60, as previously described (39) . After equilibration at this passive length for 30 min, reactivity of the arterial segments was evaluated by challenge with 1 mol/l phenylephrine (Phe). At plateau response the absence of a functional endothelium was verified by adding 10 mol/l carbachol, and only arteries that did not respond were used. The arterial segments were washed three times and, 45 min later, the vessels were restimulated with 1 mol/l Phe in the absence or presence of nitro-L-arginine methyl ester (L-NAME, 100 mol/l) or ICI-182780 (20 mol/l) added 15 min before Phe. When the plateau response was reached, cumulative concentrations of estrogens (17␣-E 2 or 17␤-E2) were added to generate concentration-relaxation curves. We also performed these experiments with 17␤-E 2:BSA conjugates, followed by another relaxation to 17␤-E 2.
Statistical analysis. For Western blotting, each value was standardized to ␤-actin from the same blot. Differences between pregnant (P) and nonpregnant (NP) groups were determined by Student's t-test. In the myotropic experiments, responses to estrogens were expressed in percentage of relaxation from the increased tone induced by Phe (1 mol/l). Concentration-relaxation curves were analyzed by nonlinear regression with Prism software (GraphPad Software, San Diego, CA):
where X is the logarithm of estrogen concentration and Y is the response obtained (% relaxation). Maximum response (E max) and the concentration of agonist producing 50% of Emax (EC50) were compared between groups by F-test (Prism). Drugs and chemicals. All salts used in these experiments were of analytical grade and obtained from Fisher Scientific (Montreal, QC, Canada) and Bio-Rad. Phe (phenylephrine hydrochloride), carbachol (carbamylcholine chloride), 17␣-E 2, and 17␤-E2 were purchased from Sigma (St. Louis, MO). ICI-182780 was procured from Tocris Cookson (Ellisville, MO). 1,3,5(10)-Estratrien-3,17␤-diol-6-one 6-carboxymethyloxime:BSA and 1,3,5(10)-estratrien-3,17␤-diol 17-hemisuccinate:BSA were purchased from Steraloids (Newport, RI). Stock solutions of ICI-182780, 17␣-E 2, and 17␤-E2 were prepared in DMSO, and 17␤-estradiol:BSA conjugates were prepared in water.
RESULTS
Uterine artery diameter, under passive tension equivalent to 60 mmHg transmural pressure, increased twofold at the end of pregnancy compared with NP rats (NP 290 Ϯ 5 m, P 560 Ϯ 7 m; P Ͻ 0.001, n ϭ 60 each). As documented previously (39), Phe (1 mol/l) induced a much larger response (almost double) in arteries of P compared with NP rats (Fig. 1, A and B, insets), and this response was not affected by preincubation with L-NAME. 17␤-E 2 evoked concentration-dependent relaxation of the uterine arteries in both groups of animals. However, relative (%) relaxation by 17␤-E 2 in endothelium-denuded uterine arteries was greater in NP compared with P rats (E max , 118 Ϯ 3% for NP vs. 106 Ϯ 4% for P; P Ͻ 0.05, n ϭ 10 each) (Fig. 1) . This larger relaxation observed in the arteries of NP rats was blocked when their tissues were preincubated with L-NAME (E max , from 118 Ϯ 3% to 100 Ϯ 6%; P Ͻ 0.01, n ϭ 10 each; Fig. 1A ). The stereoisomer 17␣-E 2 , documented to have a reduced affinity for ESR (19) , induced relaxation of the uterine arteries in both groups, but of significantly reduced magnitude compared with 17␤-E 2 . For instance, maximum relative relaxation with 17␣-E 2 in the uterine arteries of NP rats was 76 Ϯ 10% (Fig. 2B) , which was similar for the arteries of P animals. However, sensitivity to both agonists was similar (Ϫlog EC 50 ϭ 5.62 Ϯ 0.13 for 17␣-E 2 and 5.47 Ϯ 0.05 for 17␤-E 2 ; not significant).
Preincubation of arterial segments with 20 mol/l ICI-182780, an ESR antagonist, did not affect the vasorelaxant responses to 17␤-E 2 and 17␣-E 2 (Fig. 2) . Similar results were obtained with tamoxifen, an ESR antagonist (data not shown).
Moreover, 17␤-E 2 :BSA conjugates, in concentrations similar to those of 17␤-E 2 , did not produce any relaxation in endothelium-denuded uterine arteries (data not shown), but 17␤-E 2 then applied confirmed the relaxation capacity of the arterial segments.
We measured NOS expression by Western blot analysis in whole uterine and mesenteric vascular beds, the latter being representative of the systemic circulation in NP and P rats. Figure 3, A and B, show that, in both vasculatures, NOS3 expression was increased at the end of pregnancy, this difference seeming to be relatively more significant in the uterine compared with the mesenteric circulation (ϳ4.5ϫ vs. ϳ1.5ϫ). NOS2 expression in both vasculatures was undetectable ( Fig.  3C; mesenteric not shown) . In contrast, we observed that NOS1 was significantly decreased (Fig. 3E) during pregnancy in the uterine but not in the mesenteric vasculature (Fig. 3D) .
DISCUSSION
The purpose of this investigation was to characterize the vasorelaxant effects of estrogens on the VSM of uterine arteries and their difference during pregnancy. We wanted to evaluate the involvement of the different NOS and of ESR in relation to the acute relaxation induced by estrogens.
First, we observed that uterine artery diameter doubled before parturition compared with NP rats, indicating that this vessel undergoes considerable remodeling during pregnancy, as occurs in all arteries of this circulatory bed (5, 39) . Second, we demonstrated that 17␤-E 2 was able to induce concentrationdependent acute relaxation in endothelium-denuded main uterine arteries. Maximum vasodilatation was greater for NP than P rats (Fig. 1) . Furthermore, this larger relative relaxation in arteries of NP rats was reduced after preincubation with L-NAME to the level found in arterial segments from P rats (Fig. 1 ). These observations demonstrate that E 2 induces direct acute VSM relaxation of the uterine artery in rats, and they suggest some involvement of nonendothelial NO production under 17␤-E 2 application, since the arteries were denuded of their endothelium. Moreover, this NO production in uterine artery VSM is obliterated during gestation.
We have also disclosed that 17␣-E 2 induced smaller maximal relaxations than 17␤-E 2 in uterine arteries. The effect of 17␣-E 2 relative to 17␤-E 2 is a controversial issue in the Fig. 1 . Estrogen-induced relaxation of isolated uterine arterial segments from nonpregnant (A) and pregnant (B) rats and the effect of preincubation with nitro-L-arginine methyl ester (L-NAME, 100 mol/l). x-Axis depicts the log of 17␤-estradiol (E2) concentration, while y-axis shows the relative relaxation response in % of phenylephrine (Phe)-induced contraction (inset). The number of vessels used per curve was 9 or 10, all from different animals. Data points represent means Ϯ SE.
literature. Indeed, some laboratories have reported that 17␣-E 2 relaxed pig coronary arteries without achieving complete dilatation when contracted with Ca 2ϩ (34) , while others noted that 17␣-E 2 generated relaxation similar to that of 17␤-E 2 in the mesenteric arteries of rats (26) . On the other hand, 17␣-E 2 displayed only minor effects on mesenteric artery diameter over a concentration range similar to the effective vasodilatory concentration of 17␤-E 2 in the same strain of rats (37) . Our work reveals that the maximal relaxation induced by 17␣-E 2 is around two-thirds of that generated by 17␤-E 2 . Comparison remains difficult, since our experiments were carried out in different arteries (uterine) from animals of a different sex (female). Various vasculatures may present distinct contractile properties. For example, reactivity to Phe in mesenteric arteries is decreased during gestation (24, 38) , whereas it is increased in uterine arcuate arteries (39) . However, our comparative data on the effects of 17␣-E 2 and 17␤-E 2 indicate that the former acts as a partial agonist compared with the latter, because they have different efficacies with similar potencies. In the present study, maximal vascular effects of estrogens require supraphysiological concentrations of free hormone. We must take into consideration that in order to measure vasorelaxant effects of estrogen the tone of the isolated blood vessels should be increased to supraphysiological levels. High concentrations of vasorelaxant are then needed to induce measurable relaxation. It is now generally accepted that concentrations of estrogen higher than those found in plasma are needed (43) .
We also wanted to investigate whether the acute vasodilatory action of 17␤-E 2 was mediated via intracellular or membrane-localized interactions. An earlier study reported that E 2 :BSA was able to relax the pressurized mesenteric arteries of rats with intact endothelium (37) . The authors suggested that estrogens may have nongenomic effects that appear to be mediated via stereospecific interactions at the plasma membrane level. In our experiments, two different membraneimpermeant, BSA-conjugated 17␤-estradiols (BSA on C17 or C6) were used, and both failed to produce vasorelaxation of endothelium-denuded uterine arteries (data not shown), indicating that estrogen must at least penetrate the plasma membrane of smooth muscle cells to mediate its effects when endothelial cells are removed. To further evaluate ESR involvement in the vasodilatation observed in endothelium-denuded arteries, we performed the same protocol in arterial segments pretreated with ICI-182780 (Fig. 2) or tamoxifen (data not shown) before measuring the concentration-relaxation curves to 17␣-E 2 and 17␤-E 2 . These ESR antagonists did not affect relaxation generated by either 17␣-E 2 or 17␤-E 2 . This finding suggests that E 2 -induced relaxation of uterine artery VSM uses a pathway different from ESR. It has been reported that ICI-182780 was also unable to block estrogenmediated relaxation in other vasculatures, such as the mesenteric arteries of rats (37) and coronary arteries of dogs (40) , while the vasorelaxant effects of 17␤-E 2 were partially inhibited by ICI-182780 in rat aortas (6) . This indicates that the mechanism by which estrogen exerts its relaxing action could be different in distinct vascular beds and different when the endothelium is present or absent. To our knowledge, our observation is original for the uterine artery. These considerations lead us to postulate that estrogens induce vasodilatation of endothelium-denuded uterine arteries via a mechanism that does not require ESR. However, it shows stereospecificity because 17␣-E 2 also relaxed the uterine arteries with potency similar to that of 17␤-E 2 , but with about two-thirds of the latter's efficacy.
As mentioned above, GPR30 is a candidate effector for the nongenomic actions of E 2 . It has been determined that GPR30 is located in the cytoplasm and that it initiates cellular signaling from inside the cell (30) . Does the absence of relaxation to E 2 :BSA and the incapacity of ICI-182780 to block E 2 in our study mean that these responses might be mediated by GPR30? First, we should demonstrate the presence of these molecules in uterine artery VSMC. With growing interest in effectors similar to GPR30, new tools (agonists) (3) should be developed, and it will then be imperative to see whether this receptor is involved in the vasorelaxant effects of E 2 observed in uterine arteries.
We showed by Western blotting that NOS3 expression was increased in mesenteric and uterine vessels during gestation. These data are in agreement with several other studies in animals (23, 28) and humans (27) . Moreover, the relative increase of NOS3 in uterine vessels was higher than in mesenteric vessels, as also reported in ewes (23) . Despite these observations, augmented NOS3 expression cannot be evoked to explain the higher relaxation generated by 17␤-E 2 in NP compared with P rats, since our myotropic experiments were carried out in uterine arteries denuded of their endothelium, and NOS3 was found exclusively in the endothelium of uterine arteries of sheep and ewes (8, 35) . In addition, we were unable to detect NOS2 in uterine and mesenteric vessels. These results concur with several studies in which NOS2 was not seen in the uterine or resistance vessels of animals (35, 42) and humans (27) . Finally, we showed that NOS1 expression did not vary in mesenteric vessels, while it was markedly decreased in uterine vessels at the end of gestation. Another investigation reported that NOS1 expression tended to be reduced during pregnancy in human uterine arteries but did not reach significance (27) . In contrast, Rosenfeld et al. (31) noted increased NOS1 expression in the uterine arteries of ewes after daily 17␤-E 2 administration. Our data indicate that NOS1 is responsible for NO production in the VSMC of uterine arteries in NP rats. This NO production allows the larger vasorelaxation induced by 17␤-E 2 and is lost during pregnancy when NOS1 expression is decreased.
In conclusion, in the present study, we demonstrate that 17␤-E 2 and 17␣-E 2 induced relaxation of the uterine arteries by an endothelium-independent mechanism. Also, 17␤-E 2 produced larger relative relaxation in endothelium-denuded uterine arteries of NP compared with P rats because of higher NO production, believed to derive from NOS1. Because E 2 :BSA conjugates did not relax the uterine arteries, we think that estrogen can relax them by some intracellular interactions in smooth muscle cells, this response being ESR independent, since ESR antagonists were unable to block 17␤-E 2 , and 17␣-E 2 -induced relaxation. However, this acute effect of estrogens manifested some stereospecificity, indicating that a putative, receptive, specific structure is responsible for the effect. A better understanding of the mechanisms by which estrogens influence uterine vascular function and remodeling during pregnancy may help us to know what causes reduced perfusion of the utero-placental unit in clinical conditions such as intrauterine growth restriction.
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